{
    "nct_id": "NCT04887870",
    "official_title": "A Multicenter, Open-label Rollover Study of Sitravatinib Alone or in Combination With Other Anticancer Therapies in Patients With Advanced or Metastatic Solid Malignancies",
    "inclusion_criteria": "* Currently receiving sitravatinib single- agent or in combination with other therapeutic agent(s) in another Mirati- sponsored protocol\n* Currently tolerating the treatment regimen in the parent protocol\n* Experiencing clinical benefit with or without prior radiographic progression from the treatment regimen in the parent protocol in the opinion of the investigator and the investigator determines that continuing treatment is in the patient's best interest\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known or suspected presence of other cancer\n* Other life- threatening illness or organ system dysfunction compromising safety evaluation",
    "miscellaneous_criteria": ""
}